{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:54:19Z","timestamp":1785596059810,"version":"3.56.0"},"reference-count":36,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903700"],"award-info":[{"award-number":["81903700"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971982"],"award-info":[{"award-number":["81971982"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Science and technology department key R&amp;D plan emergency project","award":["2020c03123-8"],"award-info":[{"award-number":["2020c03123-8"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Venetoclax has emerged as a breakthrough for treatment of leukemia with a wide interindividual variability in pharmacokinetics. Herein, a rapid, sensitive, and reliable UPLC-MS\/MS method for quantification of venetoclax in plasma was developed and validated. The method was operated in the multiple-reaction monitoring (MRM) mode to detect venetoclax at m\/z transition 868.5 &gt; 321.0 and IS at 875.5 &gt; 321.0, respectively. Protein precipitation prior to injection into the LC-MS\/MS and the analyte was separated on an ACQUITY UPLC BEH C18 column by gradient elution with acetonitrile and 0.1% formic acid in water. Linear calibration curves were obtained in the range of 25\u20138000 ng\/mL. The specificity, recovery, matrix effect, and stability also met the acceptance criteria of FDA guidance. The method was successfully applied to analyze plasma in acute myeloid leukemia (AML) patients. The peak plasma concentration (Cmax) of venetoclax in Chinese AML patient was 2966.0 \u00b1 1595.0 ng\/mL while the trough concentration (Cmin) was 1018.0 \u00b1 729.4 ng\/mL. Additionally, Cmax and Cmin showed a positive correlation with AST levels. Furthermore, Cmax was significantly higher in the older patients. The present method can be applied for TDM of venetoclax in treatment of hematological cancers.<\/jats:p>","DOI":"10.3390\/molecules27051607","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T20:11:14Z","timestamp":1646079074000},"page":"1607","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS\/MS Method"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4418-5719","authenticated-orcid":false,"given":"Xi","family":"Yang","sequence":"first","affiliation":[{"name":"Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"He","sequence":"additional","affiliation":[{"name":"Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjuan","family":"He","sequence":"additional","affiliation":[{"name":"Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Lu","sequence":"additional","affiliation":[{"name":"Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lou","sequence":"additional","affiliation":[{"name":"Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, Department of Clinical Phamacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: Mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.tim.2017.10.009","article-title":"Not Just Antibiotics: Is Cancer Chemotherapy Driving Antimicrobial Resistance?","volume":"26","author":"Papanicolas","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_4","first-page":"393","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"26","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1158\/0008-5472.CAN-13-0940","article-title":"Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance","volume":"73","author":"Dai","year":"2013","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: Translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fphar.2019.00697","article-title":"Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","article-title":"Venetoclax: A new wave in hematooncology","volume":"61","author":"Mihalyova","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First Global Approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"ref_11","first-page":"212574","article-title":"Venetoclax: Evidence to date and clinical potential","volume":"8","author":"Desai","year":"2019","journal-title":"Drugs Context"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.16271","article-title":"The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia","volume":"188","author":"Eyre","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jcph.858","article-title":"Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model","volume":"57","author":"Freise","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00277-020-04186-0","article-title":"Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia","volume":"99","author":"Montesinos","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cpdd.395","article-title":"Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects","volume":"7","author":"Cheung","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/FTD.0000000000000701","article-title":"Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring","volume":"42","author":"Knezevic","year":"2020","journal-title":"Ther. Drug. Monit."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2012.43.5362","article-title":"Evidence for therapeutic drug monitoring of targeted anticancer therapies","volume":"30","author":"Gao","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ejca.2014.04.013","article-title":"Therapeutic drug monitoring in cancer--are we missing a trick?","volume":"50","author":"Bardin","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003088-200544020-00002","article-title":"Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review","volume":"44","author":"Huitema","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"122176","DOI":"10.1016\/j.jchromb.2020.122176","article-title":"Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies","volume":"1152","author":"Eisenmann","year":"2020","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/dmd.113.055053","article-title":"The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199","volume":"42","author":"Choo","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4155\/bio-2021-0207","article-title":"LC-MS\/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction","volume":"14","author":"Reddy","year":"2022","journal-title":"Bioanalysis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s40262-017-0625-2","article-title":"Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus","volume":"57","author":"Minocha","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/BLCTT.S177009","article-title":"The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12185-020-03024-3","article-title":"Phase 1\/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"113","author":"Izutsu","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40262-019-00788-8","article-title":"Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study","volume":"58","author":"Deng","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","article-title":"Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin\u2019s Lymphoma Patients: A Pooled Population Pharmacokinetic Analysis","volume":"18","author":"Jones","year":"2016","journal-title":"AAPS J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JCO.2007.11.0304","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group","volume":"26","author":"Ramanathan","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40262-019-00746-4","article-title":"Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment","volume":"58","author":"Salem","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_36","unstructured":"FDA, CDER, and CVM (2021, December 17). Guidance for Industry. Bioanalytical Method Validation, Available online: http:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070107.pdf."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/5\/1607\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:29:47Z","timestamp":1760135387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/5\/1607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["molecules27051607"],"URL":"https:\/\/doi.org\/10.3390\/molecules27051607","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}